Renue By Science Liposomal NMN Review (2026)

Renue By Science is one of the more credible names in a category that mostly runs on marketing: liposomal NMN. The brand leans hard on a single distinguishing claim — that its liposomal encapsulation gets more nicotinamide mononucleotide (NMN) past your gut and into your blood — and it backs that pitch with something most competitors don't have: an actual measured-NAD+ result. That makes it worth a careful, honest review. But "more evidence than its rivals" is a low bar in this category, and the headline study is far smaller and far less independent than the marketing implies. This review separates what Renue By Science can fairly claim from what it can't.

What Renue By Science is

Renue By Science is a U.S. direct-to-consumer supplement brand built around liposomal NAD+ precursors — primarily NMN, but also nicotinamide riboside (NR) and liposomal NAD+ itself, sold as capsules, sublingual powders, and topical formats. Its core marketing premise is delivery: ordinary swallowed NMN is poorly absorbed intact, so Renue wraps the molecule in liposomes (microscopic fat spheres) that, the pitch goes, shield it from stomach acid and ferry more of it into circulation.

That premise starts from a real problem. NMN and NAD+ are large, water-soluble, charged molecules that the gut is built to dismantle — only a small portion of oral NMN is directly absorbed intact, with most broken down by gut microbiota and rebuilt into NAD+ indirectly through the liver ¹. We cover that delivery problem in depth in our liposomal NAD+ evidence guide. So caring about absorption isn't silly. The question is whether Renue's specific liposomal format actually solves it — and whether the company's evidence shows that.

The headline evidence: a small, company-run NAD+ study

Here's the result the brand is known for. Renue By Science has publicly reported a small in-house study in which roughly 15 participants taking its liposomal NMN showed an approximately 84% increase in blood NAD+ levels at about four weeks. Taken at face value, that's a striking number — far larger than the ~40–50% NAD+ rise seen in the best-documented NR trials ⁶ — and it's the single biggest reason Renue stands out from generic NMN sellers.

But the honest framing matters more than the number. This study is not indexed on PubMed and has not, to our knowledge, been published in a peer-reviewed journal — a search of the biomedical literature returns no Renue By Science trial. It should be described as company-reported, not as a peer-reviewed finding. Three caveats follow directly from that:

• •It's tiny. An n of roughly 15 is a pilot-scale sample. Blood NAD+ varies substantially between people and over time, and small samples produce unstable, easily-overstated percentage changes.
• •It's industry-run. The company selling the product conducted and reported the study. That's not automatically invalid — but without independent peer review, blinding details, a placebo arm, and a published methods section, the result can't be weighted like a controlled trial.
• •It lacks a head-to-head comparator. Even if liposomal NMN raised NAD+ by 84% in these participants, the study (as reported) doesn't establish that the liposomal format did better than the same dose of ordinary NMN — which is the entire commercial claim.

So the fair read is: Renue's NAD+ result is genuinely more than most competitors offer, and it's consistent with "this product raises NAD+." It is not proof that liposomal delivery is the reason, and it shouldn't be cited as if it were trial-grade evidence.

Does liposomal NMN actually absorb better? The claim is unvalidated

This is the crux. Renue's premium price and entire identity rest on liposomal delivery outperforming plain NMN. When you search for direct human evidence, it isn't there. There is no published, peer-reviewed human trial showing that any liposomal NMN product raises blood NAD+ better than ordinary oral NMN. The liposomal-NMN papers that do exist are preclinical — topical nanogels, controlled-release vesicles for sarcopenia models, animal liver-injury work — not human oral-absorption comparisons.

Meanwhile, the trials that established NMN reliably raises blood NAD+ at all used ordinary swallowed oral doses, not liposomal ones: a dose-ranging randomized trial in healthy middle-aged adults ², a controlled study showing oral NMN safely and efficiently increased blood NAD+ ³, pharmaceutical-grade oral NMN (MIB-626) robustly raising circulating NAD+ ⁴, and a single-dose pharmacokinetic study in healthy men ⁵. The evidence base NMN's benefits rest on was built with the plain format — a point we expand in sublingual NMN vs capsules, where the same "enhanced absorption" math also turns out to be unverified.

The closest real read on whether "liposomal" delivers anything comes from a different molecule — vitamin C — the one nutrient where liposomal oral delivery has actual randomized trials. A 2025 scoping review found most studies reported higher bioavailability for the liposomal form, but with wildly varying formulations and crucially without measuring urinary elimination ⁷, and a representative double-blind crossover trial found liposomal vitamin C raised peak plasma concentration by only about 27% over standard vitamin C ⁸. A modest bump — for a small, stable molecule, in industry-funded work. Extrapolating that to NMN (far larger and more fragile, with zero human comparison data) is exactly the leap the marketing makes and the evidence doesn't support.

The benefit gap applies here too

Even granting that Renue's NMN raises NAD+, there's a second honesty check the marketing skips: raising NAD+ is not the same as feeling or aging better. Across the precursor literature, the biomarker reliably moves while downstream outcomes often don't — a 2025 systematic review and meta-analysis of NMN and NR found no reliable improvement in skeletal muscle mass or function when results were pooled ⁹, and even the better-documented NR trials raised NAD+ ~40–50% without dependable energy or cognition gains ⁶. The signals that do exist for oral NMN are small and soft — for example a trial reporting maintained walking speed and improved sleep quality in older adults ¹⁰. We walk through what NMN does and doesn't do in does NMN actually work?. So a buyer paying a liposomal premium is paying extra for an unproven absorption upgrade on top of a precursor whose felt benefits are already unproven.

Where Renue genuinely does better — and where it doesn't

To be fair to the brand, a few things are real positives:

• •It publishes a NAD+ result at all. Most NMN sellers offer zero measured data; Renue at least put a number on the table, even if it's company-reported.
• •Format range and transparency. Renue typically publishes Certificates of Analysis and offers β-NMN across multiple delivery formats, which is above the category average for disclosure — and third-party purity testing is the buying factor that actually matters, as we explain in best NMN supplements.
• •Recurring fulfillment complaints. Against that, customer reports recurringly flag shipping delays and freshness/cold-chain concerns — a relevant practical issue for a moisture- and heat-sensitive molecule like NMN, independent of the science.

On price, Renue's liposomal line typically sits at the premium end of the NMN market (current 2026 pricing), reflecting the liposomal positioning rather than a proven performance advantage. You're paying for the delivery story, and that story is not validated head-to-head.

Is Renue By Science worth it?

Put the pieces together honestly:

• •What you're reasonably buying: a transparent, β-NMN product from a brand that — unusually for the category — has at least reported a measured NAD+ increase, sold in formats with published COAs.
• •What you're not reliably buying: proof that liposomal delivery beats ordinary NMN (no published human head-to-head exists), peer-reviewed validation of the 84% figure (it's company-reported, n≈15), or proven downstream benefits on energy, strength, or aging (the precursor literature is mixed-to-null).
• •The practical caveats: premium pricing tied to an unvalidated absorption claim, plus recurring shipping/freshness complaints.

The fair verdict: if you specifically want a liposomal NMN and value a brand that publishes COAs and at least one NAD+ number, Renue By Science is a defensible pick — but treat the "84% NAD+ rise" as a company-reported pilot result, not trial-grade proof, and don't pay the liposomal premium expecting a demonstrated absorption advantage, because none has been shown in humans. For most buyers, the evidence points to choosing any well-tested NMN or NR on purity and price rather than on a delivery gimmick.

Bottom line

Renue By Science is, by the modest standards of the liposomal NMN category, one of the better-evidenced and more transparent brands — and its ~84% NAD+ result is real reporting that most rivals can't match. But that result is a small (n≈15), unpublished, industry-run pilot without a head-to-head comparator, and the central liposomal-absorption claim has never been validated against ordinary NMN in a human trial. It's a credible product wrapped in an unproven delivery promise. To compare it against the alternatives on evidence rather than marketing, see best NMN supplements rated by evidence and our best NAD+ supplements ranking; for the underlying absorption science, read the liposomal NAD+ evidence guide and the NAD+ therapy evidence pillar; and to compare brands and providers on dose, form, and testing, see our NAD+ rankings hub.

This is consumer education, not medical advice — if you have a medical condition, are pregnant, or take other medications, talk to a clinician before starting any NMN or NAD+ product.